Research
Living the science, delivering the promise
Our globally integrated R&D organization deploys more than 2,300 professionals worldwide with four main hubs in Geneva, Darmstadt,
Boston and Beijing. By structuring our activities around highly connected hubs as centers of excellence, we strengthen internal
networking and facilitate external partnerships.
Tapping into the creativity of the best scientific minds is the key to EMD Serono's innovation strategy. Our objective is
to discover novel new therapeutic molecules to bring to the clinic as quickly as possible in order to confirm the mode of
action and reach proof-of-concept in patients. Our highly specialized research and clinical development teams evaluate potential
therapeutic compounds with the goal of developing therapies for the treatment of diseases, such as multiple sclerosis and
cancer.
The global discovery pipeline currently includes approximately 70 projects prior to first-in-man studies. Worldwide, we are
pursuing over 100 company-sponsored clinical studies with the participation of thousands of patients in 60 countries around
the globe. The repertoire of EMD Serono, Inc.'s scientific innovation includes compounds in current registrational studies:
Cladribine Tablets (EMD Serono’s proprietary investigational oral formulation of cladribine)
Cladribine tablets is currently being developed as a potential treatment for patients with relapsing forms of multiple sclerosis. Cladribine is a small molecule that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS. The following cladribine tablets studies are taking place:
Cladribine tablets is currently being developed as a potential treatment for patients with relapsing forms of multiple sclerosis. Cladribine is a small molecule that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS. The following cladribine tablets studies are taking place:
-
A phase II study designed to assess the safety and efficacy of add-on cladribine tablet therapy with interferon-beta in multiple sclerosis subjects with active disease.
-
A phase III study of cladribine tablets in subjects with a first clinical demyelinating event (Clinically Isolated Syndrome) at high risk of converting to MS.
-
An extension study to further understand the long-term safety of cladribine tablets.
Safinamide
-
A Phase III study of safinamide in patients with mid-to-late stage Parkinson's Disease with motor fluctuations treated with a stable dose of levodopa (L-dopa) is currently ongoing
-
A Phase III study of safinamide in patients with early stage Parkinson’s Disease to study the efficacy and safety of two dose regimens of safinamide as add-on therapy to a stable dose of a single dopamine agonist, compared with dopamine agonist monotherapy.
BLP25 Liposome Vaccine
-
A Phase III study is ongoing to assess the efficacy and safety of Stimuvax in stage III non-small cell lung cancer (NSCLC)
-
A Phase III study is ongoing to assess the efficacy and safety of Stimuvax in combination with hormonal treatment as 1stline therapy for inoperable locally advanced, recurrent and metastatic breast cancer
Cilengitide
A Phase III study of Cilengitide is ongoing in patients with newly diagnosed glioblastoma, an aggressive type of brain cancer
A Phase III study of Cilengitide is ongoing in patients with newly diagnosed glioblastoma, an aggressive type of brain cancer
Atacicept
Currently being evaluated in Phase II/III clinical trials of systemic lupus erythematosus (SLE).
Currently being evaluated in Phase II/III clinical trials of systemic lupus erythematosus (SLE).
